CII
MDCO

CR Intrinsic Investors’s Medicines Co MDCO Stock Holding History

CR Intrinsic Investors’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-20,000
Closed -$670K – 399
2013
Q3 		$670K Buy
+20,000
New +$637K 0.02% 327

Other funds holding MDCO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAC
Smith Affiliated Capital New York $86.5B AUM 5.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CR Intrinsic Investors's MDCO Position: Q4 2013 in Review

CR Intrinsic Investors sold out of Medicines Co (MDCO) in Q4 2013, closing a stake of 20,000 shares — an estimated $670K sold.

CR Intrinsic Investors first reported a position in MDCO in Q3 2013 and held it in 1 quarter. The position peaked at $670K in Q3 2013. 182 funds tracked by Wall St. Rank hold MDCO as of Q4 2013.

  • CR Intrinsic Investors reported no remaining Medicines Co position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 20,000 Medicines Co shares in Q4 2013, an estimated $670K.
  • CR Intrinsic Investors first reported a position in Medicines Co in Q3 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's Medicines Co position peaked at $670K in Q3 2013.
  • 182 funds tracked by Wall St. Rank held Medicines Co as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.